Clinical Trial Update: Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating IPI-549 in combination with front-line therapies for triple-negative breast cancer or renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Renal Cell Carcinoma

Drugs mentioned

• IPI-549

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Breast Cancer, Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN